Abstracts - PAGE Meeting (Population Approach Group Europe)

← Back to filters

Abstracts (48)

I-08Teijo Saari

Pharmacokinetics of free hydromorphone concentrations in patients after cardiac surgery

Wednesday 10:05-11:40

I-23Christine Staatz

Dosage individulisation of tacroliums in adult kidney transplant recipients

Wednesday 10:05-11:40

I-24Gabriel Stillemans

A generic population pharmacokinetic model for tacrolimus in pediatric and adult kidney and liver allograft recipients

Wednesday 10:05-11:40

I-32Amit Taneja

From Behaviour to Target: Evaluating the putative correlation between clinical pain scales and biomarkers.

Wednesday 10:05-11:40

I-34David Ternant

Adalimumab pharmacokinetics and concentration-effect relationship in rheumatoid arthritis

Wednesday 10:05-11:40

I-45Marc Vandemeulebroecke

Literature databases: integrating information on diseases and their treatments.

Wednesday 10:05-11:40

I-47An Vermeulen

Population Pharmacokinetic Analysis of Canagliflozin, an Orally Active Inhibitor of Sodium-Glucose Co-Transporter 2 (SGLT2) for the Treatment of Patients With Type 2 Diabetes Mellitus (T2DM)

Wednesday 10:05-11:40

I-48Marie Vigan

Modelling the evolution of two biomarkers in Gaucher patients receiving enzyme replacement therapy.

Wednesday 10:05-11:40

I-54

Population pharmacokinetics and pharmacodynamics of benralizumab in healthy volunteers and asthma patients

Wednesday 10:05-11:40

I-56Franziska Weber

A linear mixed effect model describing the expression of peroxisomal ABCD transporters in CD34+ stem cell-derived immune cells of X-linked Adrenoleukodystrophy and control populations

Wednesday 10:05-11:40

I-57Sebastian Weber

PK/PD assessment of tacrolimus nephrotoxicity in liver transplantation

Wednesday 10:05-11:40

I-59Dan Wright

Bayesian dose individualisation provides good control of warfarin dosing.

Wednesday 10:05-11:40

I-62Shuying Yang

First-order longitudinal population model of FEV1 data: single-trial modeling and meta-analysis

Wednesday 10:05-11:40

I-64Rui Zhu

Population-Based Efficacy Modeling of Omalizumab in Patients with Severe Allergic Asthma Inadequately Controlled with Standard Therapy

Wednesday 10:05-11:40

II-16Aurelie Gautier

Pharmacokinetics of Canakinumab and pharmacodynamics of IL-1β binding in cryopyrin associated periodic fever, a step towards personalized medicine

Wednesday 14:50-16:20

II-25Sophie Gisbert

Is it possible to use the plasma and urine pharmacokinetics of a monoclonal antibody (mAb) as an early marker of efficacy in membranous nephropathy (MN)?

Wednesday 14:50-16:20

II-51Jeremie Guedj

Modeling Early Viral Kinetics with Alisporivir: Interferon-free Treatment and SVR Predictions in HCV G2/3 patients

Wednesday 14:50-16:20

II-52Claire Johnston

A population approach to investigating hepatic intrinsic clearance in old age: Pharmacokinetics of paracetamol and its metabolites

Wednesday 14:50-16:20

II-57Ana Novakovic

Application of Item Response Theory to EDSS Modeling in Multiple Sclerosis

Wednesday 14:50-16:20

III-05Cédric Laouenan

Modelling early viral hepatitis C kinetics in compensated cirrhotic treatment-experienced patients treated with triple therapy including telaprevir or boceprevir

Thursday 10:05-11:35

III-08Donghwan Lee

Development of a Disease Progression Model in Korean Patients with Type 2 Diabetes Mellitus(T2DM)

Thursday 10:05-11:35

III-09Joomi Lee

Population pharmacokinetics of prothionamide in Korean tuberculosis patients

Thursday 10:05-11:35

III-11Tarek Leil

PK-PD Modeling using 4β-Hydroxycholesterol to Predict CYP3A Mediated Drug Interactions

Thursday 10:05-11:35

III-12Annabelle Lemenuel Diot

How to improve the prediction of Sustained Virologic Response (SVR) for Hepatitis C patients using early Viral Load (VL) Information

Thursday 10:05-11:35

III-21Dan Lu

Semi-mechanistic Multiple-analyte Population Model of Antibody-drug-conjugate Pharmacokinetics

Thursday 10:05-11:35

III-36Enrica Mezzalana

A Target-Mediated Drug Disposition model integrated with a T lymphocyte pharmacodynamic model for Otelixizumab.

Thursday 10:05-11:35

III-40

Mixed Effects Modeling to Quantify the Effect of Empagliflozin Exposure on the Renal Glucose Threshold in Patients with Type 2 Diabetes Mellitus

Thursday 10:05-11:35

III-41Morris Muliaditan

Model-based evaluation of iron overload in patients affected by transfusion dependent diseases

Thursday 10:05-11:35

III-42Flora Musuamba-Tshinanu

Modelling of disease progression and drug effects in preclinical models of neuropathic pain

Thursday 10:05-11:35

III-44Thu Thuy Nguyen

Mechanistic Model to Characterize and Predict Fecal Excretion of Ciprofloxacin Resistant Enterobacteria with Various Dosage Regimens

Thursday 10:05-11:35

III-50Jaeseong Oh

A Population Pharmacokinetic-Pharmacodynamic Analysis of Fimasartan in Patients with Mild to Moderate Essential Hypertension

Thursday 10:05-11:35

III-54Sean Oosterholt

PKPD modelling of PGE2 inhibition and dose selection of a novel COX-2 inhibitor in humans.

Thursday 10:05-11:35

III-56

Population pharmacokinetic model of sildenafil describing first-pass effect to its metabolite

Thursday 10:05-11:35

III-57Sung Min Park

Population pharmacokinetic/pharmacodynamic modeling for transformed binary effect data of triflusal in healthy Korean male volunteers

Thursday 10:05-11:35

IV-03

Mathematical Modelling of the Spread of Hepatitis C among Drug Users, effects of heterogeneity.

Thursday 14:55-16:20

IV-08Helena Edlund

Clinical relevance of albumin concentration in patients with Crohn’s disease treated with infliximab for recommendations on dosing regimen adjustments

Thursday 14:55-16:20

IV-09Franc Andreu Solduga

Development of a Bayesian Estimator for Tacrolimus in Kidney Transplant Patients: A Population Pharmacokinetic approach.

Thursday 14:55-16:20

IV-15Shanshan Bi

Population Pharmacokinetic/Pharmacodynamic Modeling of Two Novel Neutral Endopeptidase Inhibitors in Healthy Subjects

Thursday 14:55-16:20

IV-17Roberto Bizzotto

Characterization of binding between OSM and mAb in RA patient study: an extension to TMDD models

Thursday 14:55-16:20

IV-19Karina Blei

Mechanism of Action of Jellyfish (Carukia barnesi) Envenomation and its Cardiovascular Effects Resulting in Irukandji Syndrome

Thursday 14:55-16:20

IV-20Michael Block

Predicting the antihypertensive effect of Candesartan-Nifedipine combinations based on public benchmarking data.

Thursday 14:55-16:20

IV-21Michael Block

Physiologically-based PK/PD modeling for a dynamic cardiovascular system: structure and applications

Thursday 14:55-16:20

IV-36Kalayanee Chairat

A population pharmacokinetics and pharmacodynamics of oseltamivir and oseltamivir carboxylate in adults and children infected with influenza virus A(H1N1)pdm09

Thursday 14:55-16:20

IV-41Chao Chen

A mechanistic model for the involvement of the neonatal Fc receptor in IgG disposition

Thursday 14:55-16:20

IV-42Chunli Chen

Design optimization for characterization of rifampicin pharmacokinetics in mouse

Thursday 14:55-16:20

IV-58Willem de Winter

Population PK/PD analysis linking the direct acute effects of canagliflozin on renal glucose reabsorption to the overall effects of canagliflozin on long-term glucose control using HbA1c as the response marker from clinical studies

Thursday 14:55-16:20

IV-59Joost DeJongh

A population PK-PD model for effects of Sipoglitazar on FPG and HbA1c in patients with type II diabetes.

Thursday 14:55-16:20

IV-60Paolo Denti

A semi-physiological model for rifampicin and rifapentine CYP3A induction on midazolam pharmacokinetics.

Thursday 14:55-16:20